Pfizer announced positive top-line results from its year-long Phase III trial of etrasimod for the treatment of ulcerative colitis (UC). The company plans to pursue regulatory filings for the drug later this year.

“For patients suffering with moderate to severe ulcerative colitis, these most recent data further demonstrate the substantial potential benefits of this medicine and clearly confirm its ability to achieve significant induction of remission at 12 weeks.” said Michael Corbo, Pfizer’s chief development officer.